The new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors submitted by Ryvu Therapeutics S.A.
Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
Introduction of the Series I Shares to trading on the main market operated by the WSE and designation of the last day of listing of Rights to Series I Shares
Determination of the issue price of Series I shares issued by Ryvu Therapeutics S.A., the number of Series I shares to be offered for subscription by Ryvu Therapeutics S.A. and execution of the pricing supplement to the placement agreement
Ryvu Therapeutics S.A. concludes a placement agreement and commences the book-building process for an offering by way of private subscription of new Series I ordinary bearer shares issued by Ryvu Therapeutics S.A.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy